Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric and Esophagogastric Junction Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06123494
What this trial is testing

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Jiangsu HengRui Medicine Co., Ltd. 360
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06241469
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study

Who this might be right for
Gastric CancerGastroEsophageal CancerAdenocarcinoma
Wu Jun 40
Large-scale testing (Phase 3)Study completedNCT02178956
What this trial is testing

BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Sumitomo Pharma America, Inc. 714
Early research (Phase 1)Study completedNCT05327231
What this trial is testing

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Who this might be right for
Gastric Cancer
InxMed (Shanghai) Co., Ltd. 33
Not applicableActive Not RecruitingNCT05165264
What this trial is testing

Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Bristol-Myers Squibb 600
Testing effectiveness (Phase 2)Study completedNCT00259987
What this trial is testing

Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus

Who this might be right for
Adenocarcinoma
GlaxoSmithKline 24
Large-scale testing (Phase 3)Active Not RecruitingNCT06356311
What this trial is testing

Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

Who this might be right for
Gastroesophageal Cancer
Merck Sharp & Dohme LLC 450
Testing effectiveness (Phase 2)Study completedNCT01504256
What this trial is testing

Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas

Who this might be right for
Gastric Adenocarcinoma With Peritoneal CarcinomatosisSiewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal CarcinomatosisSiewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis
AIO-Studien-gGmbH 42
Testing effectiveness (Phase 2)Ended earlyNCT03840967
What this trial is testing

A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Who this might be right for
Esophageal CancerGastric CancerAdenocarcinoma
Shadia Jalal, MD 14
Testing effectiveness (Phase 2)Ended earlyNCT04604132
What this trial is testing

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Who this might be right for
Gastric Adenocarcinoma
Basilea Pharmaceutica 47
Testing effectiveness (Phase 2)UnknownNCT04890392
What this trial is testing

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Who this might be right for
Advanced Gastric CancerAdvanced Gastroesophageal Junction Adenocarcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 20
Large-scale testing (Phase 3)Study completedNCT04882241
What this trial is testing

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Merck Sharp & Dohme LLC 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT07776639
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Yongxu Jia 34
Testing effectiveness (Phase 2)UnknownNCT05739045
What this trial is testing

Nivolumab Combined With SOX Used in the Perioperative Treatment

Who this might be right for
Immune SuppressionGastric Cancer
Xiangdong Cheng 46
Testing effectiveness (Phase 2)Looking for participantsNCT06163729
What this trial is testing

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

Who this might be right for
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 68
Large-scale testing (Phase 3)Not Yet RecruitingNCT06093425
What this trial is testing

Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal-junction CancerAdvanced Cancer
Transcenta Therapeutics (Hangzhou) Co., Ltd. 820
Early research (Phase 1)Not Yet RecruitingNCT06748872
What this trial is testing

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Who this might be right for
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more
Medigene AG 55
Not applicableApproved For MarketingNCT02065765
What this trial is testing

International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerMetastatic Adenocarcinoma of the Gastroesophageal Junction
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT03918499
What this trial is testing

IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8+15 more
City of Hope Medical Center 9
Not applicableStudy completedNCT04161781
What this trial is testing

PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer

Who this might be right for
Esophagogastric CancerEsophagus CancerEsophageal Cancer+4 more
Memorial Sloan Kettering Cancer Center 10
Next Page